Whitepapers

The Strategic Value of In-House Delumping for Homogeneous API Production

August 27, 2026

Delumping is an established operation in pharmaceutical manufacturing, used to produce more homogeneous, free-flowing powders across drug substance and drug product processes. When agglomeration is left unaddressed, it can affect powder flow, charging, homogeneity, downstream processing, cycle time and yield.

In this technical paper, Kim Geurts, Scientist PR&D and Manufacturing, Enabling Chemistry, explains how Ardena implemented in-house delumping at its Drug Substance site in Oss and what the capability has delivered in practice — from qualification using deliberately agglomerated lactose monohydrate to successful processing of highly potent OEB-5 material in a GMP client program, achieving a 98% yield.

Gain a deeper understanding of

  • Why controlled delumping can improve powder flow, homogeneity and downstream process robustness without unnecessarily reducing primary particle size
  • How bringing delumping in-house can reduce external dependencies, project timelines and operational risk
  • How Ardena Oss has implemented and qualified a flexible, GMP-ready delumping capability for development and highly potent manufacturing programs

Want to Learn More?

Explore our full range of services and discover how Ardena can support your drug development journey.

Technical Papers & White Papers